NGeneBio Statistics

Total Valuation

NGeneBio has a market cap or net worth of KRW 33.43 billion. The enterprise value is 35.69 billion.

Market Cap	33.43B
Enterprise Value	35.69B

Important Dates

The last earnings date was Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

NGeneBio has 19.82 million shares outstanding. The number of shares has increased by 11.90% in one year.

Current Share Class	n/a
Shares Outstanding	19.82M
Shares Change (YoY)	+11.90%
Shares Change (QoQ)	+40.32%
Owned by Insiders (%)	13.18%
Owned by Institutions (%)	1.33%
Float	15.85M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.21
PB Ratio	1.80
P/TBV Ratio	3.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.83
EV / Sales	6.27
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.84

Financial Position

The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.51.

Current Ratio	0.93
Quick Ratio	0.66
Debt / Equity	0.51
Debt / EBITDA	n/a
Debt / FCF	-0.72
Interest Coverage	-8.91

Financial Efficiency

Return on equity (ROE) is -82.15% and return on invested capital (ROIC) is -36.93%.

Return on Equity (ROE)	-82.15%
Return on Assets (ROA)	-26.71%
Return on Invested Capital (ROIC)	-36.93%
Return on Capital Employed (ROCE)	-78.70%
Revenue Per Employee	81.30M
Profits Per Employee	-180.39M
Employee Count	70
Asset Turnover	0.15
Inventory Turnover	1.91

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -69.70% in the last 52 weeks. The beta is 1.18, so NGeneBio's price volatility has been higher than the market average.

Beta (5Y)	1.18
52-Week Price Change	-69.70%
50-Day Moving Average	1,689.70
200-Day Moving Average	2,487.57
Relative Strength Index (RSI)	51.70
Average Volume (20 Days)	152,266

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NGeneBio had revenue of KRW 5.69 billion and -12.63 billion in losses. Loss per share was -890.00.

Revenue	5.69B
Gross Profit	2.08B
Operating Income	-16.08B
Pretax Income	-14.27B
Net Income	-12.63B
EBITDA	-13.14B
EBIT	-16.08B
Loss Per Share	-890.00

Full Income Statement

Balance Sheet

The company has 7.50 billion in cash and 9.02 billion in debt, giving a net cash position of -1.52 billion or -76.84 per share.

Cash & Cash Equivalents	7.50B
Total Debt	9.02B
Net Cash	-1.52B
Net Cash Per Share	-76.84
Equity (Book Value)	17.71B
Book Value Per Share	938.71
Working Capital	-852.15M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -12.43 billion and capital expenditures -135.37 million, giving a free cash flow of -12.57 billion.

Operating Cash Flow	-12.43B
Capital Expenditures	-135.37M
Free Cash Flow	-12.57B
FCF Per Share	-634.05

Full Cash Flow Statement

Margins

Gross margin is 36.63%, with operating and profit margins of -282.47% and -221.89%.

Gross Margin	36.63%
Operating Margin	-282.47%
Pretax Margin	-250.77%
Profit Margin	-221.89%
EBITDA Margin	-230.88%
EBIT Margin	-282.47%
FCF Margin	n/a

Dividends & Yields

NGeneBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.90%
Shareholder Yield	-11.90%
Earnings Yield	-37.77%
FCF Yield	-37.58%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NGeneBio has an Altman Z-Score of -2.41. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.41
Piotroski F-Score	n/a